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S U M M A R Y
Objectives: To determine the role of colonizers in the causation of ventilator-associated pneumonia (VAP)
and the value of routine pre-VAP endotracheal aspirate (EA) cultures in appropriately treating VAP.
Methods: A prospective observational cohort study was conducted over a period of 15 months. Two
hundred patients on mechanical ventilation for > 48 h were studied.
Results: Acinetobacter spp (33.7%) and Pseudomonas spp (29.8%) were the most common colonizers. Of
the 200 patients, 36 developed VAP. In 20 VAP patients, the pre-VAP EA culture-based strategy was not
useful. However, in the remaining 16 VAP patients, a pre-VAP EA culture-based strategy would have
appropriately treated 13 (81%; 95% conﬁdence interval (CI) 62–100%), in comparison to only nine (56%;
95% CI 32–80%) by the American Thoracic Society (ATS) strategy. The seven patients in whom the ATS
guidelines were inappropriate had Acinetobacter spp and Pseudomonas spp resistant to the higher
antibiotics recommended by the ATS formultidrug-resistant pathogens. The positive predictive values of
Pseudomonas aeruginosa, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus
(MRSA) isolated from pre-VAP EA cultures were 88%, 83%, and 100%, respectively.
Conclusion: VAP patients should be treated based on ATS guidelines, but whenever P. aeruginosa, A.
baumannii, and MRSA are isolated from pre-VAP EA cultures, the initial antibiotic therapy should be
extended to treat these.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Ventilator-associated pneumonia (VAP) is the most frequent
intensive care unit (ICU)-acquired infection, occurring in 9–24% of
patients intubated for longer than 48 h.1 It is associated with
increased morbidity, prolonged hospitalization, and increased
healthcare costs.2,3 The diagnosis of VAP remains controversial
because of the absence of a ‘gold standard’ for diagnosis.4 Lung
biopsy, which can be considered as the gold standard, is not
feasible in the clinical setting.5 Therefore, the American Thoracic
Society (ATS) guidelines recommend a quantitative distal sampling
of the lung, by bronchoscopic or non-bronchoscopic approaches, to
improve the speciﬁcity of diagnostic methods.4 The diagnostic
challenge is further complicated by the need to differentiate
between pathogenic microorganisms and colonizing ﬂora.* Corresponding author. Current address: Department of Microbiology, Mahatma
Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry 607
402, India. Tel.: +91 9843094673.
E-mail address: noyaljoseph@yahoo.com (N.M. Joseph).
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doi:10.1016/j.ijid.2010.02.2248Upper airway colonization is considered an important predis-
posing factor for the development of VAP.6 Secretions of the lower
respiratory tract obtained by bronchoscopy may accurately
diagnose the pathogens.7 However, it may do so too late in the
course of VAP to reduce the morbidity, as bronchoscopy is usually
done at the advanced stages. Therefore, culture of endotracheal
aspirates (EA) is more relied on as it is less invasive and can be
obtained early in the course of infection.
Routine endotracheal aspirate cultures of critically ill patients
in ICUs may be predictive of patients who are at high risk of
invasive disease, and may guide the selection of appropriate
empirical therapy based on the predominant pathogens identiﬁed
in these cultures in the event of the development of VAP.8 But the
role and accuracy of such approaches remain controversial. In a
study in which 1626 respiratory surveillance samples were
collected, surveillance cultures effectively predicted only one
episode of VAP and one of tracheobronchitis.9 But in another study,
the tracheal surveillance cultures predicted the pathogen in 67 out
of 110 episodes of nosocomial pneumonia.10 Similarly, in a study
from France, routine weekly endotracheal aspirate cultures guided
adequate antibiotic therapy in 85% of VAP cases.11 Since there areses. Published by Elsevier Ltd. All rights reserved.
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to re-evaluate the role of colonizers in predicting VAP pathogens.
Failure to treat the potential pathogens increases the morbidity
and mortality, while overenthusiastic treatment of the colonizing
organisms results in unnecessary exposure to broad-spectrum
antibiotics and predisposes to infection with multidrug-resistant
(MDR) pathogens.12
The primary aim of our study was to determine if pre-VAP EA
cultures have any supplementary role to play, along with the ATS
guidelines, in the treatment of VAP. The secondary objectives of
this study were: (1) to identify the common colonizers and their
role in the causation of VAP, (2) to determine the value of routine
tracheal aspirate cultures performed before the onset of VAP in
predicting the causative microorganisms and selecting effective
empirical antimicrobial therapy in the event of subsequent VAP,
and (3) to compare the appropriateness of treatment based on the
pre-VAP EA strategy with that of the ATS strategy.
2. Materials and methods
2.1. Setting and subjects
A prospective observational cohort studywas conducted during
a period of 15months fromOctober 2006 to December 2007, in the
departments of microbiology, medicine, and anesthesiology and
critical care at Jawaharlal Institute of Postgraduate Medical
Education and Research (JIPMER), a tertiary care hospital in
Pondicherry, India. All consecutive adult patients on mechanical
ventilation (MV) for >48 h in the medicine intensive care unit
(MICU) and critical care unit (CCU) were included in this study.
Patients with pneumonia prior to MV or within 48 h of MV were
excluded. Only the ﬁrst episode of VAP was evaluated. This study
was approved by the research and ethics committees of the
Institute, and informed consent was obtained from the patient’s
next of kin.
2.2. ICU setting
There are eight, well-spaced beds in each ICU, but there is no
partition between them. There are three nurses posted to an ICU
with a nurse to patient ratio of 1:2.7. The ICU ﬂoors are routinely
mopped with Lysol and the other surfaces including the trolleys,
beds, andwindow sills are cleanedwith ethanol three times a day.
The bed covers are changed once every two days or earlier if
soiled, and whenever a new patient is admitted. The choice of
antibiotics for the treatment of VAP patients was left to the
discretion of the attending physician. The physicians were
treating the patients on an individual basis using a combination
of the ATS strategy, surveillance cultures, presence of risk factors
for MDR pathogens, and their knowledge of the local microbial
ﬂora in the ICU and their antibiograms, without undue emphasis
on any single strategy.
2.3. Data collection
The following data were collected from the patients enrolled in
the study: age, gender, underlying illness, duration of hospitaliza-
tion, duration of mechanical ventilation, and details of prior
antibiotic therapy. Other relevant data were recorded from
medical records, bedside charts, radiographic reports, and reports
of microbiological studies.
2.4. Routine surveillance
EAwere obtained every 3 days from all patients included in the
study. Quantitative culture of the EA was performed immediatelyin the microbiology laboratory. EA was serially diluted in sterile
normal saline to 1/10, 1/100, and 1/1000, and 0.01 ml of 1/1000
dilution was inoculated on 5% sheep blood agar. After incubation
at 37 8C in a 5% CO2 incubator for 24 h, a colony count was done
and expressed as number of colony-forming units per ml (CFU/
ml). The number of CFU/ml is equal to the number of colonies on
the agar plate  dilution factor  inoculation factor. Therefore the
presence of even a single colony on the blood agar after
inoculating 0.01 ml of 1/1000 times diluted EA was interpreted
as more than 105 CFU/ml.13 The organisms isolated from the
clinical specimens were identiﬁed based on standard bacterio-
logical procedures.14 The susceptibility of the isolates to some
routinely used antibiotics was determined by the Kirby–Bauer
disk diffusion method.15
2.5. Diagnosis of VAP
All patients included in this study were monitored at frequent
intervals for the development of VAP using clinical and microbio-
logical criteria, until discharge or death. The clinical pulmonary
infection score (CPIS) based on six clinical assessments, eachworth
0–2 points, including fever, leukocyte count, quantity and
purulence of tracheal secretions, oxygenation, type of radiographic
abnormality, and results of sputum culture and Gram stain, was
used in patients clinically suspected of VAP.16 Microbiological
conﬁrmation was based on a positive Gram stain (>10 polymor-
phonuclear cells/low power ﬁeld and 1 bacteria/oil immersion
ﬁeld) and quantitative EA culture showing 105 CFU/ml.5,17,18
Patients fulﬁlling both the clinical (CPIS >6) and the microbiolog-
ical criteria were diagnosed to be suffering from VAP.
Patients developing VAP within the ﬁrst four days of MV were
classiﬁed as having early-onset VAP,while those developing VAP at
ﬁve or more days after the initiation of MV were classiﬁed as
having late-onset VAP.4
2.6. Colonizers
Thosemicroorganisms isolated from the EA of themechanically
ventilated patients at a concentration of less than 105 CFU/ml in
both the patients with VAP and thosewithout VAPwere referred to
as colonizers in this study.
2.7. Evaluation of the pre-VAP EA strategy
The bacteria isolated from pre-VAP EA cultures and those
present at a concentration of 105 CFU/ml in the quantitative EA
culture obtained after VAP developed were considered to be same
if they belonged to the same species and had similar antibiotic
susceptibility patterns. We compared the antibiotic therapy that
would have been prescribed based on the pre-VAP EA strategywith
that of the ATS strategy.
2.8. Statistical analysis
Results were expressed as mean  standard deviation (SD).
Comparison of the mean age of patients with and without VAP was
carried out using an unpaired Student’s t-test. All tests of
signiﬁcance were two-tailed. The Fisher’s exact test was done to
compare the use of broad-spectrum antibiotics according to the
different strategies; SPSS version 16.0 statistics software was used
(SPSS Inc., Chicago, IL, USA). The sensitivity, speciﬁcity, positive
predictive value, and negative predictive value were determined
using GraphPad InStat version 3.00 for Windows 95 (GraphPad
Software, San Diego, CA, USA). Likelihood ratios were calculated
according to Deeks and Altman.19 All p-values of < 0.05 were
considered statistically signiﬁcant.
Table 1
Demographic data for the 36 VAP patients
Characteristic Value
Age, years (mean SD) 41.414.7
Gender
Male 24 (66.7%)
Female 12 (33.3%)
Underlying diseases
Poisoning 10
Neuromuscular disorders (GBS, MND, tetanus) 9
Intra-abdominal diseases 4
Snake bite 4
CNS infections (encephalitis/meningitis) 3
Pregnancy-related disorders 2
Trauma (fracture, cerebral hemorrhage) 2
Cardiovascular disease 1
Leptospirosis 1
Median time to occurrence of VAP
(25th percentile, 75th percentile)
5 (3, 7) days
Median No. of pre-VAP EA cultures
performed before diagnosis of VAP
(25th percentile, 75th percentile)
1 (0, 2)
Median delay between pre-VAP EA and
onset of VAP (25th percentile, 75th percentile)
4 (3, 8) days
VAP, ventilator-associated pneumonia; SD, standard deviation; GBS, Guillain–Barre´
syndrome; MND, motor neuron disease; EA, endotracheal aspirate.
N.M. Joseph et al. / International Journal of Infectious Diseases 14 (2010) e723–e729 e7253. Results
Two hundred patients on MV for >48 h were prospectively
followed in this study. Among them, 36 (18%) were diagnosed to
have developed VAP during their ICU stay. The incidence of VAP
was 22.94 per 1000 ventilator-days. Among the remaining 164
patients, 17 had a discrepancy between the CPIS score and
quantitative EA culture. In six cases CPIS was >6, but the
quantitative EA culture was negative. In these six patients, the
CPIS was considered to be falsely high, because of an abnormal
chest X-ray due to a past episode of tuberculosis, traumatic injury
to the lung, or cardiopulmonary edema secondary to underlying
cardiovascular disease and/or transient fever and leukocytosis
following trauma or surgery and/or poor oxygenation due to
underlying hemodynamic instability. However, all these patients
were afebrile or only transiently febrile and the CPIS was elevated
only for a short period andmost of them improvedwithin next few
days, ruling out the possibility of VAP. So these six patients were
not considered to be suffering from VAP. In another 11 cases, the
quantitative EA culture was positive, but CPIS was < 6. All of these
were afebrile, their chest X-rays were normal, and the subsequent
quantitative EA cultures were negative. They also showed rapid
improvement in their general condition without any intervention
or change in antibiotics, excluding the diagnosis of VAP. So they
were also not categorized as VAP patients.
Themean  standard deviation (SD) age of patients with VAPwas
41.4  14. 7 years (range 15–75 years). Themean  SD age of patients
without VAP was 36.8  16.3 years (range 13–80 years); age of VAP
patients vs. non-VAP patients, p-value = 0.1170. In our study, 21
(58.3%) cases were late-onset VAP, while 15 (41.7%) cases were early-
onset VAP. The mean  SD day of onset of VAP was 6.17  4.7 (range
2–24). The demographic data of the patients with VAP are
summarized in Table 1. Most cases of VAP were caused by Gram-
negative bacteria, which accounted for 80.9% of the causative
organisms. Acinetobacter baumannii (23.4%) and Pseudomonas aeru-
ginosa (21.3%) were the predominant Gram-negative bacteria
associated with VAP, and Staphylococcus aureus (14.9%) was the
most common Gram-positive bacterium among patients with VAP.
We studied the proportion of VAP patients who had the importantTable 2
Colonizers of mechanically ventilated patients
Colonizer No. of isolates
(N=205)
Ciproﬂoxacin
resistance (%)
Gram-negative bacteria (n=186)
Non-fermenters (n=130)
Acinetobacter baumannii 56 95
Acinetobacter lwofﬁi 13 92
Pseudomonas aeruginosa 49 65
Pseudomonas spp 12 67
Enterobacteriaceae (n=55)
Escherichia coli 21 95
Klebsiella pneumoniae 19 74
Citrobacter diversus 4 100
Enterobacter spp 2 100
Providencia spp 5 100
Proteus spp 3 67
Morganella morganii 1 0
Other (n=1)
Haemophilus inﬂuenzae 1 -
Gram-positive bacteria (n=17)
MSSA 7 14
MRSA 7 86
Streptococcus pyogenes 1 -
Streptococcus pneumoniae 1 -
Enterococcus faecalis 1 -
Fungi (n=2)
Candida spp (non-albicans) 2 -
MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphrisk factors forMDRpathogens. Of the 36 VAP patients, 31 (86.1%) had
received antimicrobial therapy in the preceding 90 days, while 28
(77.8%) were hospitalized for ﬁve days or more. Of the 28 non-
fermenters, 22 (78.6%) were isolated from patients with late-onset
VAP, while six (21.4%) were isolated from those with early-onset VAP.
However, all six early-onset VAP patients, from whom the non-
fermenters were isolated, had risk factors for MDR pathogens.
3.1. Colonizers of the respiratory tract in mechanically ventilated
patients
Acinetobacter spp (33.7%) and Pseudomonas spp (29.8%) were the
most commonorganisms colonizing the respiratory tract in patients
on MV. Members of the Enterobacteriaceae were present as
colonizers in 26.8% of themechanically ventilated patients (Table 2).Amikacin
resistance (%)
Ceftazidime
resistance (%)
Meropenem
resistance (%)
86 96 45
92 92 39
43 59 8
75 58 17
19 90 0
16 63 5
25 100 0
50 50 0
60 100 0
100 100 0
100 100 0
- - -
- - -
- - -
- - -
- - -
- - -
- - -
ylococcus aureus.
Figure 1. Comparison of the colonization rates of important VAP pathogens.
Figure 2. Role of routine serial cultures in predicting VAP pathogens.
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positive colonizer, methicillin-resistant S. aureus (MRSA) account-
ing for 50% of these. Streptococcus pyogenes, Streptococcus
pneumoniae, Enterococcus faecalis, and Candida spp (non-albicans)
were the other relatively less common colonizers (Table 2).
3.2. Colonization rates of important VAP pathogens
As 13 patients developed VAP as early as day 2 or 3 of
mechanical ventilation, pre-VAP EA cultures could not be
performed. Pre-VAP EA cultures were performed only for the
remaining 23 VAP cases. Colonization was detected in 14 of the 23
(60.9%) assessable VAP cases. Many of the pathogenic micro-
organisms causing VAP were initially present as colonizers in the
respiratory tract followed by subsequent development of VAP.
Colonization rates were relatively higher with non-fermenter and
MRSA than Enterobacteriaceae (Figure 1).
3.3. Role of routine serial cultures in predicting VAP pathogens
The role of routine serial EA culture in predicting VAP pathogens
is shown in Figure 2. In 14 of the 23 assessable cases (60.9%), either
one or all of the VAP pathogens were isolated by routine serial
culture prior to the diagnosis of VAP, while in seven (30.4%) cases
the specimens collected prior to the diagnosis of VAP were sterile.
3.4. Comparison of routine serial EA cultures (pre-VAP) and
quantitative culture of EA obtained after the development of VAP
Of the 205 colonizers, only 16 (7.8%) subsequently caused VAP.
Of the 16 bacteria belonging to the same species that were isolated
from both pre-VAP EA cultures and conﬁrmatory quantitative EA
cultures of the respective patients, 13 had exactly the same
antibiograms, while the remaining three had slightly different
antibiograms. Two A. baumannii appeared initially sensitive to
amikacin, but later when isolated from conﬁrmatory quantitative
EA cultures were resistant to amikacin. Similarly one P. aeruginosa
isolated from pre-VAP EA culture was sensitive tomeropenem, butTable 3
Diagnostic value of prior colonization in predicting VAP pathogens
VAP pathogen Sensitivity (95% CI) Speciﬁcity (95% CI)
Pseudomonas aeruginosa 70 (35–93) 96 (80–100)
Acinetobacter baumannii 45 (17–77) 96 (80–100)
MRSA 33 (0.8–91) 100 (89–100)
Othera 13 (3–34) 52 (30–74)
VAP, ventilator-associated pneumonia; CI, conﬁdence interval; PPV, positive predictiv
negative likelihood ratio; MRSA, methicillin-resistant Staphylococcus aureus.
a Includes all the microorganisms other than Pseudomonas aeruginosa, Acinetobacterthe isolate from conﬁrmatory quantitative EA culture was
resistant. Only 14 of the 31 (45.2%) pathogens causing late-onset
VAP and two of the 16 (12.5%) pathogens causing early-onset VAP
were isolated previously from pre-VAP EA cultures.
3.5. Diagnostic value of prior colonization in predicting VAP
The diagnostic value of previous colonization by different
pathogens in predicting subsequent VAP caused by these micro-
organisms in terms of sensitivity, speciﬁcity, predictive values and
likelihood ratios is summarized in Table 3.
3.6. Appropriateness of antibiotic therapy based on pre-VAP EA
cultures vs. the ATS strategy
As pre-VAP EA cultures were not performed in 13 VAP cases for
the reasons mentioned above and in another seven cases the EA
cultures were sterile, we could not apply the pre-VAP EA culture-
based strategy to those 20 patients. Hence we evaluated both the
ATS strategy and the pre-VAP EA strategy only in the remaining 16
assessable VAP cases. According to ATS guidelines, the antibiotic
treatment would have been appropriate in nine of the 16
assessable VAP cases (56%; 95% conﬁdence interval (CI) 32–80%)
with a piperacillin–tazobactam and aminoglycoside-based regi-
men, or in seven of the 16 assessable VAP cases (44%; 95% CI 20–
68%) with a carbapenem–aminoglycoside-based regimen. Howev-
er a strategy based on the pre-VAP EA cultures would have
appropriately treated 13 of 16 assessable VAP cases (81%; 95% CI
62–100%). In the majority of the cases in which the ATS strategy
would have failed, MDR pathogens such as Acinetobacter spp and
Pseudomonas spp were present, which were resistant to even the
higher antibiotics like meropenem, piperacillin–tazobactam,
ceftazidime, gatiﬂoxacin and amikacin, recommended by the
ATS for the treatment of MDR pathogens. Of the 14 Acinetobacter
spp isolated from VAP patients, ﬁve (36%) and 10 (71%) were
resistant to piperacillin–tazobactam and meropenem, respective-PPV (95% CI) NPV (95% CI) Likelihood ratios
LR-pos LR-neg
88 (47–100) 89 (72–98) 18 0.3
83 (36–100) 80 (61–92) 11 0.6
100 (3–100) 94 (81–99) 1 0.7
23 (5–54) 35 (19–55) 0.3 1.7
e value; NPV, negative predictive value; LR-pos, positive likelihood ratio; LR-neg,
baumannii, and MRSA.
Table 4
Antibiotic(s) used for the treatment of VAP patients according to different strategies
Antibiotic(s) Number of patients who
would receive a particular
antibiotic(s) based on:
Pre-VAP EA
strategy
ATS
strategy
Ceftriaxone 0 1
Ceftazidime 1 0
Amikacin + meropenem 2 0
Erythromycin + amikacin 1 0
Meropenem 4 0
Piperacillin–tazobactam 2 0
Ticarcillin 1 0
Vancomycin 1 0
Piperacillin–tazobactam +
amikacin
0 35
Cefoperazone–sulbactam +
levoﬂoxacin + meropenem
1 0
Colistin + rifampin + meropenem 3 0
No appropriate antibiotic was
suggested by the strategy
20 0
VAP, ventilator-associated pneumonia; EA, endotracheal aspirate; ATS, American
Thoracic Society.
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were resistant to piperacillin–tazobactam and meropenem,
respectively.
3.7. Rational use of antibiotics according to different strategies
If the ATS strategy had been used it would have led to
prescription of additional unnecessary antibiotics in four of the 36
cases (11.1%). Similarly, the pre-VAP EA culture-based strategy
would have led to the use of unnecessary broad-spectrum
antibiotics in one of the 16 assessable cases (6.3%). There was
no statistically signiﬁcant difference in the use of broad-spectrum
antibiotics according to these strategies (p-value 1.000).
Based on the ATS strategy, higher antibiotics like meropenem,
piperacillin–tazobactam, cefoperazone–sulbactam, ticarcillin, co-
listin, and vancomycin would have been used in 35 of the 36 cases
(97%; 95% CI 92–100%). Similarly, according to pre-VAP EA
cultures, higher antibiotics would have been used in 14 of the
16 assessable VAP cases (88%; 95% CI 72–100%); p-value 0.2208 vs.
ATS strategy (Table 4). The ATS strategy would have led to the use
of these higher antibiotics in 35 of the 36 cases, as 21 patients had
late-onset VAP and 14 of the 15 early-onset VAP patients had at
least one of the risk factors for MDR pathogens.
4. Discussion
In our study a relatively high proportion of the patients
developed early-onset VAP. Even in a large US-based study
involving 842 VAP cases, about 63% of patients developed VAP
at about 48 h of MV.3 The interaction of several risk factors during
the initial days of MV puts these patients at higher risk. Moreover,
our hospital, being a tertiary care hospital, most of our patients
would have received medical assistance at several primary
healthcare centers before approaching us, and hence were
probably already colonized with multiple pathogens, which could
have contributed to the early occurrence of VAP. Acinetobacter spp
(33.7%) and Pseudomonas spp (29.8%) were identiﬁed as the most
common organisms colonizing the respiratory tract of the patients
on MV. Among the S. aureus colonizing the respiratory tract, 50%
were MRSA. Colonization of the respiratory tract with Acineto-
bacter spp, Pseudomonas spp, and MRSA may originate from
endogenous sources such as the oropharynx or the stomach, or
from exogenous sources such as contaminated respiratoryinstruments, infective aerosols from the ICU environment, and
contaminated hands and apparel of the healthcare workers. These
non-fermenters and MRSA referred to as ‘MDR’ pathogens,
characteristically display high levels of antibiotic resistance and
are therefore more difﬁcult to treat in the event of the occurrence
of VAP.4,20 The majority of our VAP patients had risk factors for
MDR pathogens, which explains the high rate of colonization by
these MDR pathogens.
By repeated assessment of colonization and infection of the
lower airways using EA, we found that VAP was preceded by
colonization in 60.9% of the 23 assessable VAP cases. The
performance of routine quantitative culture of surveillance EA
samples allowed us to prospectively and accurately determine the
incidence and sequence of lower respiratory tract colonization to
infection in patients on MV. Among the VAP pathogens, 46.4% of
non-fermenters and 33.3% of MRSA were initially present as
colonizers in the respiratory tract followed by subsequent
development of VAP. Hence, colonization by these organisms
may predispose to VAP. Two A. baumannii and one P. aeruginosa
isolated from pre-VAP EA cultures showed slightly different
antibiograms when recovered later from conﬁrmatory quantita-
tive EA cultures. But despite the slightly discordant antibiograms
we have considered them to be same, as disk diffusion is not
always reproducible even when the same strain is repeatedly
tested, and has an inherent weakness of showing difference in
antimicrobial susceptibility often related to environmental factors
or plasmids.21 In patients with such discordant antibiograms, the
treating physician should ideally discuss with the microbiologist
whether the antibiotic showing variable activity against the isolate
can be used to treat the patient. The minimum inhibitory
concentration (MIC) of that antibiotic should be determined
whenever possible and if the isolate is found susceptible, then the
patient can be treated with it.
In a study by Hayon et al., all the organisms ultimately
responsible for VAP were previously recovered from only 35% of
the respiratory secretions, emphasizing the limitations of serial
culture.22 In the above study, it was also shown that of the 220
microorganisms responsible for VAP, only 21(10%), 17 (8%), 8 (4%),
and 7 (3%) were isolated from catheter tip, routine surveillance
cultures (nasal, throat and skin swabs), urine, and blood,
respectively.22 However, in a study by Jung et al., the results of
pre-VAP EA cultures were concordant with the results of
bronchoalveolar lavage (BAL) in 72% of cases.11 Similarly in a
study by Michel et al., pre-VAP EA had identiﬁed the same
microorganisms (with the same antibiotic resistance patterns) in
83% of the VAP cases.8 In our study, pre-VAP EA cultures predicted
the VAP pathogens in 60.9% of assessable VAP cases. There was a
relatively high occurrence (41.7%) of early-onset VAP in our study
in contrast to only 29% early-onset VAP in the study byMichel et al.
As a result of the increased number of early-onset cases, only a few
or no pre-VAP EA specimens were available for many cases,
resulting in the low recovery of VAP pathogens in our study. The
other possibility for the lower recovery of VAP pathogens in pre-
VAP EA could be the early administration of broad-spectrum
antibiotics in most of our patients.
In a study by Depuydt et al., the sensitivity of tracheal
surveillance cultures to predict MDR VAP pathogens was 69%.23
Though in our study the sensitivity of pre-VAP EA culture to predict
A. baumannii was relatively low (45%), the sensitivity for the
prediction of P. aeruginosa was 70%, which is comparable with the
study by Depuydt et al.
As prior colonization by P. aeruginosa, A. baumannii, and MRSA
had a very good speciﬁcity (96–100%) and a high negative
predictive value (80–94%), it can accurately exclude most patients
without infection by these MDR pathogens; however, as their
sensitivity (33–70%) is low, failure to retrieve these organisms does
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organisms also had very good positive and negative likelihood
ratios, suggesting that the presence or absence of colonization by
these organisms can provide strong evidence to rule in or rule out
VAP pathogens. Although another recent study also noted that the
speciﬁcity of these pathogens was high,24 there are no studies to
support antibiotic treatment of these colonizers to prevent VAP.
However, a randomized, multicenter study has conclusively
proved that antimicrobial treatment of ventilator-associated
tracheobronchitis (VAT) is associated with a reduction in the
number of days ofMV and also lower rates of VAP.25 Craven et al. in
their clinical opinion have also suggested that targeted antibiotic
therapy for VAT may be a new paradigm for the prevention of
VAP.26 Colonization bymicroorganisms other than P. aeruginosa, A.
baumannii, and MRSA had very poor sensitivity, speciﬁcity, PPV,
NPV and likelihood ratios. So colonization by these organisms will
not be useful in predicting the subsequent occurrence of VAP by
these organisms.
In themajority (55.6%) of the VAP cases, treatment based on the
pre-VAP EA culture results was not useful in guiding empirical
antimicrobial therapy, as the pre-VAP specimens were sterile or
pre-VAP EA specimens could not be collected. But whenever one or
more microorganisms were retrieved from the pre-VAP EA
specimens, the treatment was appropriate in 81% of cases based
on this strategy. Michel et al. have also shown that routine EA
performed twice aweek is useful in prescribing adequate antibiotic
therapy in 95% of the patients in whom a VAP is ultimately
diagnosed by BAL culture.8
There is a delay of 24–48 h before EA or BAL quantitative
culture results and antibiotic sensitivity proﬁles become available
to the treating physician. Therefore, the critical care physicians
generally use a combination of anti-pseudomonal cephalosporin
or carbapenem or b-lactam/b-lactamase inhibitor with anti-
pseudomonal ﬂuoroquinolone, with or without vancomycin,
according to the ATS guidelines, for the treatment of patients
with risk factors for MDR pathogens.4 However, this empirical
regimen recommended by the ATS may not be effective against
MDR A. baumannii andMDR P. aeruginosa resistant to carbapenem
and piperacillin–tazobactam. Our study showed that though pre-
VAP cultures were not available in the majority of our cases,
whenever they were positive, this could guide more appropriate
therapy than the ATS strategy. So, knowledge about the
susceptibility pattern of the isolates from pre-VAP EA cultures
may guide the clinician to appropriately treat such potential MDR
pathogens. Combination regimens using colistin, polymyxin, and
tigecycline have been reported to be useful in treating such
infections.27,28 Moreover, the PPV of MDR organisms such as P.
aeruginosa, A. baumannii, and MRSA isolated from pre-VAP EA
cultures in predicting the VAP pathogens were high enough to
justify extending the spectrum of initial antibiotic therapy to deal
with these MDR pathogens. So, based on our results, we suggest
that VAP patientsmay be treated aswidely practiced, based on the
ATS strategy, but that whenever the above-mentioned MDR
pathogens are isolated from pre-VAP EA cultures, the antibiotic
therapy should be extended to treat them. This modiﬁcation will
be especially useful in settings such as ourswhereMDRpathogens
not responding to the routine higher antibiotics are prevalent. The
treatment recommended for meropenem-resistant MDR Acine-
tobacter spp is intravenous colistin combined with rifampin with
or without imipenem or tigecycline.27,29 Similarly the preferred
treatment for MDR P. aeruginosa resistant to meropenem and
piperacillin–tazobactam is colistin or levoﬂoxacin in combination
with imipenemor ceftazidime/cefoperazonewith sulbactum.28,30
Pirracchio et al., found high speciﬁcities and likelihood ratios for
upper airway samples to predict the microorganisms involved in
VAP. So, like us, they have also suggested that upper airwaysamples might provide adjunctive assistance in selecting the
therapy for VAP.31
Hayon et al. observed that MDR organisms such as MRSA, P.
aeruginosa, and A. baumannii isolated from surveillance cultures
had low positive predictive values of 62%, 52%, and 24%,
respectively, in predicting the occurrence of VAP by these
pathogens.22 Therefore, the treatment based on surveillance
cultures appeared to expose many patients to unnecessary
broad-spectrum antibiotics. However, in our ICUs with a relatively
high prevalence of these MDR pathogens, we found that MRSA, P.
aeruginosa, and A. baumannii isolated from pre-VAP EA cultures
had high positive predictive values of 100%, 88%, and 83%,
respectively. Moreover, we observed that there was no signiﬁcant
increase in the use of broad-spectrum antibiotics with the pre-VAP
EA strategy compared to the ATS strategy. Therefore, we suggest
that in ICUs with a high prevalence of MDR pathogens, treatment
based on pre-VAP EA cultures will not expose patients to
unnecessary broad-spectrum antibiotics. Similarly, Depuydt
et al. also found that the surveillance cultures performed in an
ICU with a high prevalence of MDR pathogens contributed to high
rates of early appropriate antibiotic therapy with limited use of
broad-spectrum antimicrobials.23
As the studywas conducted in a resource-limited setting, only a
small number of patientswith VAPwere studied, which is themain
limitation of our study. The small numbers of pathogens led to very
large 95% CI for predictive values, limiting the accuracy of the
results. Therefore, the results of our study need to be further
conﬁrmed by larger clinical trials, as this may have a major impact
on the treatment of VAP, which is a great challenge for critical care
physicians, especially in developing countries. The other limitation
of our study is that we did not perform quantitative culture of
bronchoscopically collected samples like BAL for the conﬁrmation
of VAP.
5. Conclusions
To conclude, Acinetobacter spp and Pseudomonas spp were the
most common organisms colonizing the respiratory tract of the
patients on MV. VAP patients should be treated based on ATS
guidelines, but whenever MDR pathogens like P. aeruginosa, A.
baumannii, and MRSA are isolated from pre-VAP EA cultures, the
initial antibiotic therapy should be extended to treat these. Thus
pre-VAP EA cultures could be a useful adjunct to the ATS strategy
for ensuring appropriate treatment of VAP patients, especially in
places where resistance to carbapenems and other second-line
antibiotics is fairly rampant.
Conﬂict of interest: No conﬂict of interest to declare.
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